At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Acomprosatedrug
Likely dose
Acomprosate 333 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Evaluating the Safety of Acamprosate for Alcohol Use Disorder in Alcohol-related Liver Disease
In Brief
A Phase 2 clinical trial evaluating Acomprosate for Alcohol-related Liver Disease. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Is acamprosate safe to use in individuals with liver disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol-related Liver Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartSep 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedFeb 27, 2020
Enrollment StartSep 21, 2020
Primary CompletionJan 5, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.3 years ago
Interventions
Acomprosatedrug
Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months